Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Afferi

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
European Urology Focus|August 22, 2021
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre CollaborationChiara Lonati, Philipp Baumeister, Luca Afferi, et al.
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
World Journal of Urology|February 26, 2022
Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaborationChiara Lonati, Luca Afferi, Andrea Mari, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
European Urology Oncology|February 14, 2024
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
European Urology Oncology|June 17, 2022
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder CancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
European Urology Focus|August 22, 2021
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre CollaborationChiara Lonati, Philipp Baumeister, Luca Afferi, et al.
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
World Journal of Urology|February 26, 2022
Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaborationChiara Lonati, Luca Afferi, Andrea Mari, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
European Urology Oncology|February 14, 2024
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
European Urology Oncology|June 17, 2022
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder CancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
Pageof 13